Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERI-LONG vericiguat for post-COVID-19 syndrome
2021-005494-11Phase 2Active
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-COVID syndrome and myalgic encephalomyelitis (ME) comparing Vericiguat with Placebo (2 arms). Primary endpoint: Change in SF-36 Physical Function score. Started Dec 2022; status: active.
02
Drugs
vericiguat
03
Conditions
post-COVID syndromemyalgic encephalomyelitis (ME)
Beyond the preview
Go deeper on 2021-005494-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005494-11.